Core Viewpoint - 康哲药业 has successfully completed its secondary listing on the Singapore Exchange, marking a significant milestone in its development and international capital market strategy [1] Company Overview - 康哲药业 is a specialized pharmaceutical company with nearly 30 years of deep roots in China, having established a differentiated product portfolio in key therapeutic areas such as cardiovascular, central nervous system, digestive system, dermatology, and ophthalmology since its listing on the Hong Kong Stock Exchange in 2010 [1] Strategic Intent - The founder and CEO of 康哲药业, 林刚, emphasized that the Singapore listing will enhance the company's international capital market presence and accelerate its internationalization strategy in the pharmaceutical industry, aiming to improve the entire ecosystem of drug research, production, and sales [1] Market Positioning - 新交所's executive vice president, 保得胜, highlighted that 康哲药业's listing reflects the growing demand for medical innovation and accessibility in Asia, positioning the company to expand its business footprint in Southeast Asia and connect with international investors [1] Financial Metrics - At the time of listing, 康哲药业 had a market capitalization of approximately 286.4 billion HKD (around 46.7 billion SGD), and it became the 40th listed company in the healthcare sector on the Singapore Exchange [1] - The opening price of 康哲药业's shares was 2.05 SGD [1]
新加坡交易所证券市场欢迎康哲药业在主板上市